Compare PulteGroup, Inc. (PHM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? PulteGroup, Inc. trades at $126.7 (market cap $23.67B), while Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3× PulteGroup, Inc.'s market cap, and PulteGroup, Inc. pays the higher dividend (0.84%). Which is the better fit depends on your goals.
| PHM | REGN | |
|---|---|---|
Market Cap | $23.67B | $70.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $812.27 |
52-Week Low | $110.11 | $545.46 |
Enterprise Value | $23.63B | $64.74B |
Dividend Yield | 0.84% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $124.26, down 1.44% over the past day, with technical indicators showing a bearish trend. The stock exhibits strong profitability with a net income margin of 12.14% and ROE of 16.18%, though recent quarters saw mixed earnings results. Valuation ratios remain attractive with a P/E of 11.91 and P/S of 1.44. Recent news highlights institutional activity and anticipation for Q2 2026 earnings, with the company expanding communities amid housing market challenges.
The outlook for PHM is cautiously optimistic, supported by solid fundamentals and a consensus price target of $146.50 implying 18% upside. Risks include margin pressure from high mortgage rates and competitive discounts. Analyst sentiment is balanced with 45% buy ratings, but investors should monitor earnings execution and housing demand trends for sustained growth.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
